Trial · NCT00512096
Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis
NCT00512096, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2010-12-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis. Trials, record NCT00512096. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00512096
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis
- NCT number
- NCT00512096
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 30 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Penile Cancer
- Interventions
- Ifosfamide, Paclitaxel (Taxol), Cisplatin
- First posted
- 2007-08-07
- Last updated
- 2012-08-01
- Results first posted
- 2010-12-08
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Pathologic Complete Remission (pCR) | restaging with second and fourth 21-day cycles followed by surgery | Histopathologic assessment of surgical resection to confirm Pathologoic Complete Remission. Complete remission defined as disappearance of all target lesions. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Pathologic Complete Remission (pCR) | restaging with second and fourth 21-day cycles followed by surgery | Participants who completed chemotherapy without progression then had surgical resection. | participants | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Pathologic Complete Remission (pCR) | Cisplatin + Ifosfamide + Paclitaxel | 3 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cisplatin + Ifosfamide + Paclitaxel | 30 | |
| Overall Study | COMPLETED | Cisplatin + Ifosfamide + Paclitaxel | 23 | |
| Overall Study | NOT COMPLETED | Cisplatin + Ifosfamide + Paclitaxel | 7 |
Source ClinicalTrials.gov
Adverse events11
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | anemia | Blood and lymphatic system disorders | Cisplatin + Ifosfamide + Paclitaxel | 1 | 30 | 1 |
| other | Neutropenia | Blood and lymphatic system disorders | Cisplatin + Ifosfamide + Paclitaxel | 1 | 30 | 1 |
| other | infection | Infections and infestations | Cisplatin + Ifosfamide + Paclitaxel | 5 | 30 | 5 |
| other | deep vein thrombosis | Vascular disorders | Cisplatin + Ifosfamide + Paclitaxel | 1 | 30 | 1 |
| other | central venous catheter related thrombosis | Vascular disorders | Cisplatin + Ifosfamide + Paclitaxel | 1 | 30 | 1 |
| other | febrile neutropenia | Blood and lymphatic system disorders | Cisplatin + Ifosfamide + Paclitaxel | 1 | 30 | 1 |
| other | hyperglycemia | Metabolism and nutrition disorders | Cisplatin + Ifosfamide + Paclitaxel | 1 | 30 | 1 |
| other | neuropathy motor | Nervous system disorders | Cisplatin + Ifosfamide + Paclitaxel | 1 | 30 | 1 |
| other | thrombocytopenia | Blood and lymphatic system disorders | Cisplatin + Ifosfamide + Paclitaxel | 1 | 30 | 1 |
| serious | allergic reaction | Immune system disorders | Cisplatin + Ifosfamide + Paclitaxel | 1 | 23 | 1 |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cisplatin + Ifosfamide + Paclitaxel | ||
| Total, other adverse events | Cisplatin + Ifosfamide + Paclitaxel | 13 | 30 |
| Total, serious adverse events | Cisplatin + Ifosfamide + Paclitaxel | 3 | 30 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 20625118 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00512096
GET https://conductscience.org/api/trials/v1/NCT00512096/registered